Asia
OrbusNeich Medical Enrolls First Patient in Japan Trial of Coronary Balloon
OrbusNeich Medical Group (HKG:6929) enrolled the first patient in a clinical trial of its proprietary coronary paclitaxel drug-coated balloon in Japan.The trial targets patients suffering from coronary artery disease, with a focus on the treatment of de novo lesions in both small and large vessels and in-stent restenosis, according to a Wednesday Hong Kong bourse filing.
HKG:6929
